Tower Research Capital LLC (Trc) Satsuma Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.7 - $1.07 $5,796 - $8,859	8,280 New	8,280 $6,000
Q3 2022 Nov 10, 2022	BUY	$4.19 - $7.95 $460 - $874	110 New	110 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $4,615 - $7,662	-1,782 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$3.78 - $5.32 $6,010 - $8,458	1,590 Added 828.13%	1,782 $7,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $18,737 - $28,173	-4,515 Reduced 95.92%	192 $1,000
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $10,015 - $15,817	2,206 Added 88.2%	4,707 $22,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $40,046 - $60,486	-8,343 Reduced 76.94%	2,501 $18,000
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $10,926 - $17,167	2,391 Added 28.29%	10,844 $64,000
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $136,120 - $194,621	-38,236 Reduced 81.9%	8,453 $39,000
Q3 2020 Nov 16, 2020	BUY	$3.85 - $28.47 $174,312 - $1.29 Million	45,276 Added 3204.25%	46,689 $182,000
Q2 2020 Aug 13, 2020	BUY	$16.01 - $34.69 $22,622 - $49,016	1,413 New	1,413 $41,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.